Exchange: SIX Industry: Pharmaceuticals, Biotechnology & Life Sciences
2.43% CHF3.37
America/New_York / 2 mai 2024 @ 05:17
FUNDAMENTALS | |
---|---|
MarketCap: | 110.77 mill |
EPS: | -1.890 |
P/E: | -1.780 |
Earnings Date: | Mar 15, 2024 |
SharesOutstanding: | 32.87 mill |
Avg Daily Volume: | 0.0117 mill |
RATING 2024-05-02 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.780 | sector: PE 25.29 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.10x |
Company: PE -1.780 | industry: PE 17.08 |
DISCOUNTED CASH FLOW VALUE |
---|
CHF4.52 (34.25%) CHF1.154 |
Date: 2024-05-02 |
Expected Trading Range (DAY) |
---|
CHF 3.16 - 3.59 ( +/- 6.38%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | CHF3.37 (2.43% ) |
Volume | 0.0121 mill |
Avg. Vol. | 0.0117 mill |
% of Avg. Vol | 103.44 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.